The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

The primary endpoint in PREVAIL is Myasthenia Gravis-Activities of Daily Living total score improvement from baseline, and ...

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN ...

AstraZeneca has bagged a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR ...

UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

AstraZeneca’s investigational therapy gefurulimab has delivered positive results in the pivotal Phase III PREVAIL trial for ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...